Literature DB >> 22531438

Femtomolar Fab binding affinities to a protein target by alternative CDR residue co-optimization strategies without phage or cell surface display.

Christian Votsmeier1, Hanna Plittersdorf, Oliver Hesse, Andreas Scheidig, Michael Strerath, Uwe Gritzan, Klaus Pellengahr, Peter Scholz, Andrea Eicker, David Myszka, Wayne M Coco, Ulrich Haupts.   

Abstract

In therapeutic or diagnostic antibody discovery, affinity maturation is frequently required to optimize binding properties. In some cases, achieving very high affinity is challenging using the display-based optimization technologies. Here we present an approach that begins with the creation and clonal, quantitative analysis of soluble Fab libraries with complete diversification in adjacent residue pairs encompassing every complementarity-determining region position. This was followed by alternative recombination approaches and high throughput screening to co-optimize large sets of the found improving mutations. We applied this approach to the affinity maturation of the anti-tumor necrosis factor antibody adalimumab and achieved ~500-fold affinity improvement, resulting in femtomolar binding. To our knowledge, this is the first report of the in vitro engineering of a femtomolar affinity antibody against a protein target without display screening. We compare our findings to a previous report that employed extensive mutagenesis and recombination libraries with yeast display screening. The present approach is widely applicable to the most challenging of affinity maturation efforts.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22531438      PMCID: PMC3355236          DOI: 10.4161/mabs.19981

Source DB:  PubMed          Journal:  MAbs        ISSN: 1942-0862            Impact factor:   5.857


  23 in total

1.  Directed evolution of antibody fragments with monovalent femtomolar antigen-binding affinity.

Authors:  E T Boder; K S Midelfort; K D Wittrup
Journal:  Proc Natl Acad Sci U S A       Date:  2000-09-26       Impact factor: 11.205

2.  Simultaneous humanization and affinity optimization of monoclonal antibodies.

Authors:  Herren Wu
Journal:  Methods Mol Biol       Date:  2003

3.  Adalimumab.

Authors:  Bornadata Bain; Melanie Brazil
Journal:  Nat Rev Drug Discov       Date:  2003-09       Impact factor: 84.694

Review 4.  Selecting and screening recombinant antibody libraries.

Authors:  Hennie R Hoogenboom
Journal:  Nat Biotechnol       Date:  2005-09       Impact factor: 54.908

5.  Antibody-antigen interactions: contact analysis and binding site topography.

Authors:  R M MacCallum; A C Martin; J M Thornton
Journal:  J Mol Biol       Date:  1996-10-11       Impact factor: 5.469

Review 6.  In vitro selection from protein and peptide libraries.

Authors:  T Clackson; J A Wells
Journal:  Trends Biotechnol       Date:  1994-05       Impact factor: 19.536

7.  An M13 phage library displaying random 38-amino-acid peptides as a source of novel sequences with affinity to selected targets.

Authors:  B K Kay; N B Adey; Y S He; J P Manfredi; A H Mataragnon; D M Fowlkes
Journal:  Gene       Date:  1993-06-15       Impact factor: 3.688

8.  Kinetic and affinity limits on antibodies produced during immune responses.

Authors:  J Foote; H N Eisen
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

9.  Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore.

Authors:  L C Santora; Z Kaymakcalan; P Sakorafas; I S Krull; K Grant
Journal:  Anal Biochem       Date:  2001-12-15       Impact factor: 3.365

10.  Control of receptor-induced signaling complex formation by the kinetics of ligand/receptor interaction.

Authors:  Anja Krippner-Heidenreich; Fabian Tübing; Susanne Bryde; Sylvia Willi; Gudrun Zimmermann; Peter Scheurich
Journal:  J Biol Chem       Date:  2002-09-04       Impact factor: 5.157

View more
  6 in total

1.  Alteration of Electrostatic Surface Potential Enhances Affinity and Tumor Killing Properties of Anti-ganglioside GD2 Monoclonal Antibody hu3F8.

Authors:  Qi Zhao; Mahiuddin Ahmed; Hong-fen Guo; Irene Y Cheung; Nai-Kong V Cheung
Journal:  J Biol Chem       Date:  2015-04-07       Impact factor: 5.157

Review 2.  Functional analysis of the anti-adalimumab response using patient-derived monoclonal antibodies.

Authors:  Pauline A van Schouwenburg; Simone Kruithof; Christian Votsmeier; Karin van Schie; Margreet H Hart; Rob N de Jong; Esther E L van Buren; Marieke van Ham; Lucien Aarden; Gertjan Wolbink; Diana Wouters; Theo Rispens
Journal:  J Biol Chem       Date:  2014-10-17       Impact factor: 5.157

3.  Simultaneous affinity maturation and developability enhancement using natural liability-free CDRs.

Authors:  Andre A R Teixeira; Sara D'Angelo; M Frank Erasmus; Camila Leal-Lopes; Fortunato Ferrara; Laura P Spector; Leslie Naranjo; Esteban Molina; Tamara Max; Ashley DeAguero; Katherine Perea; Shaun Stewart; Rebecca A Buonpane; Horacio G Nastri; Andrew R M Bradbury
Journal:  MAbs       Date:  2022 Jan-Dec       Impact factor: 6.440

4.  The influence of antibody fragment format on phage display based affinity maturation of IgG.

Authors:  Miriam Steinwand; Patrick Droste; André Frenzel; Michael Hust; Stefan Dübel; Thomas Schirrmann
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

5.  Therapeutic TNF Inhibitors can Differentially Stabilize Trimeric TNF by Inhibiting Monomer Exchange.

Authors:  Karin A van Schie; Pleuni Ooijevaar-de Heer; Lisanne Dijk; Simone Kruithof; Gertjan Wolbink; Theo Rispens
Journal:  Sci Rep       Date:  2016-09-08       Impact factor: 4.379

6.  An end-to-end automated platform process for high-throughput engineering of next-generation multi-specific antibody therapeutics.

Authors:  Norbert Furtmann; Marion Schneider; Nadja Spindler; Bjoern Steinmann; Ziyu Li; Ingo Focken; Joachim Meyer; Dilyana Dimova; Katja Kroll; Wulf Dirk Leuschner; Audrey Debeaumont; Magali Mathieu; Christian Lange; Werner Dittrich; Jochen Kruip; Thorsten Schmidt; Joerg Birkenfeld
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.